Kelonia Therapeutics

About:

Kelonia Therapeutics is developing a new wave of genetic medicines using its next-generation vivo gene delivery platform.

Website: https://keloniatx.com

Twitter/X: KeloniaTx

Top Investors: Horizons Ventures, Venrock, Alta Partners

Description:

Kelonia Therapeutics is developing a new wave of genetic medicines using its next-generation vivo gene delivery platform. The company's cutting-edge in vivo gene delivery technology is simple and elegant, relying on a few potent lentiviral vector-like particles to precisely and efficiently deliver genetic cargo to the desired target tissue, and only that tissue, every time. To deliver genetic cargo only to the desired tissue, the lentiviral vector gene delivery platform employs a simple and elegant solution based on decades of research, development, and technical experience. Kelonia's mission is to develop a new wave of accessible genetic medicines that will transform the lives of patients suffering from a broad range of conditions.

Total Funding Amount:

$50M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

2017-01-01

Founders:

Kevin Friedman, Michael Birnbaum, Michael Fischbach, Molly Perkins

Number of Employees:

11-50

Last Funding Date:

2022-04-28

IPO Status:

Private

Industries:

© 2025 bioDAO.ai